Long A T, Kenne E, Jung R, Fuchs T A, Renné T
Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Division of Clinical Chemistry, Department of Molecular Medicine and Surgery and Center for Molecular Medicine, Karolinska Institutet and University Hospital, Stockholm, Sweden.
J Thromb Haemost. 2016 Mar;14(3):427-37. doi: 10.1111/jth.13235. Epub 2016 Feb 9.
The contact system is a plasma protease cascade initiated by factor XII (FXII) that activates the proinflammatory kallikrein-kinin system and the procoagulant intrinsic coagulation pathway. Anionic surfaces induce FXII zymogen activation to form proteolytically active FXIIa. Bacterial surfaces also have the ability to activate contact system proteins, indicating an important role for host defense using the cooperation of the inflammatory and coagulation pathways. Recent research has shown that inorganic polyphosphate found in platelets activates FXII in vivo and can induce coagulation in pathological thrombus formation. Experimental studies have shown that interference with FXII provides thromboprotection without a therapy-associated increase in bleeding, renewing interest in the FXIIa-driven intrinsic pathway of coagulation as a therapeutic target. This review summarizes how the contact system acts as the cross-road of inflammation, coagulation, and innate immunity.
接触系统是一种由因子 XII(FXII)启动的血浆蛋白酶级联反应,它激活促炎激肽释放酶-激肽系统和促凝内源性凝血途径。阴离子表面诱导 FXII 酶原激活形成具有蛋白水解活性的 FXIIa。细菌表面也具有激活接触系统蛋白的能力,这表明炎症和凝血途径协同作用在宿主防御中具有重要作用。最近的研究表明,血小板中发现的无机多磷酸盐在体内激活 FXII,并可在病理性血栓形成中诱导凝血。实验研究表明,干扰 FXII 可提供血栓保护作用,且不会因治疗导致出血增加,这重新引发了人们对将 FXIIa 驱动的内源性凝血途径作为治疗靶点的兴趣。本综述总结了接触系统如何作为炎症、凝血和先天免疫的交叉点发挥作用。